Heat Biologics Inc (NASDAQ:HTBX) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 390,000 shares, a decrease of 8.2% from the August 30th total of 424,900 shares. Based on an average trading volume of 197,100 shares, the days-to-cover ratio is currently 2.0 days. Currently, 1.2% of the shares of the company are sold short.
Separately, Brookline Capital Management assumed coverage on shares of Heat Biologics in a research note on Monday, July 29th. They set a “buy” rating and a $8.00 price objective on the stock.
NASDAQ HTBX traded down $0.01 on Thursday, hitting $0.38. The stock had a trading volume of 89,000 shares, compared to its average volume of 381,735. Heat Biologics has a one year low of $0.35 and a one year high of $2.10. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.01. The stock has a market cap of $14.08 million, a price-to-earnings ratio of -0.42 and a beta of 1.76. The company’s 50-day moving average is $0.50 and its two-hundred day moving average is $0.74.
Heat Biologics (NASDAQ:HTBX) last posted its earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. Heat Biologics had a negative net margin of 386.16% and a negative return on equity of 75.51%. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.91 million. On average, sell-side analysts anticipate that Heat Biologics will post -0.65 earnings per share for the current year.
A hedge fund recently raised its stake in Heat Biologics stock. Vanguard Group Inc. grew its position in Heat Biologics Inc (NASDAQ:HTBX) by 6.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,327,660 shares of the biopharmaceutical company’s stock after purchasing an additional 84,400 shares during the period. Vanguard Group Inc. owned approximately 3.90% of Heat Biologics worth $909,000 as of its most recent SEC filing. 5.55% of the stock is owned by institutional investors.
About Heat Biologics
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
See Also: Recession
Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.